Eli Lilly slips as obesity pill trails Novo's oral Wegovy

ReutersApr 24, 2026 3:54 PM

View all comments（0）



Shares of Eli Lilly LLY.N fall 3.8% to $882.75

Lilly's newly launched oral weight loss pill, Foundayo, recorded 3,707 U.S. prescriptions in its second week after launch, up from 1,390 in its first week

Rival Novo Nordisk's NOVOb.CO oral Wegovy pill had 18,410 prescriptions in its second week, compared with 3,071 in its debut week

U.S.-listed shares of Novo rise 5.7% to $40.70

J.P. Morgan analyst said Foundayo's slower ramp versus oral Wegovy is not surprising due to Novo's earlier launch and brand recognition

"Investors will be scrutinizing the numbers, and believe that Foundayo scripts totaling just 20% of what oral Wegovy achieved during their first full week could cause the stock to be weak today" - Truist analyst Srikripa Devarakonda

Including session's move, LLY down 17.9%, NVO down 19.9% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Japan and South Korea Stocks Rise in Early Trade, Samsung Rebounds Over 3%, Trump Arrives in Beijing With Tech Giants

TradingKey - Asian stock markets generally trended higher in Thursday morning trading. The Nikkei 225 opened 0.14% higher, with intraday gains expanding to 200 points at one stage, while SoftBank Group tracked the advance with a gain of over 1%. South Korea’s KOSPI opened 0.4% higher and rallied quickly, with intraday gains reaching 1% and surpassing the 7,900-point mark. LG Electronics led the index constituents, rising more than 5%.

Anthropic in Talks for Massive $30 Billion Funding, Valuation May Join Trillion-Dollar Ranks

TradingKey - On May 12, Eastern Time, Bloomberg reported that AI startup Anthropic is in preliminary discussions with investors to raise at least $30 billion in new capital at a pre-money valuation exceeding $900 billion. If the deal is finalized, it would mark the company's largest funding round to

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

TradingKey - During the Asian trading session on May 11, SK Hynix shares rose by more than 15% at one point, hitting an all-time intraday high of 1.949 million KRW, with its market capitalization surpassing $900 billion. The year-to-date cumulative gain is approximately 197.03%, with the share price nearly tripling.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools